Content of the article
VANCOUVER, British Columbia and MONTREAL — Versant Companies today announced that it will be filing an alert report regarding the ownership of securities of Repare Therapeutics Inc. (the “Company”) by Versant Venture Capital VI, LP, Versant Vantage I, LP, Versant Venture Capital V, LP , Versant Venture Capital V (Canada) LP, Versant Ophthalmic Affiliates Fund I, LP and Versant Affiliates Fund V, LP (collectively, the “Versant Funds”).
On June 6, 2022, certain of the Versant Funds distributed an aggregate of 700,000 common shares in the capital of the Company (“Common Shares”) pursuant to a discretionary distribution to their respective partners for no additional consideration. The 700,000 ordinary shares distributed on June 6, 2022 are called the “Distributed Shares”.
Content of the article
Immediately prior to the disposition of the Distributed Shares, the Versant Funds beneficially owned, controlled or directed 4,244,862 common shares of the Company, representing approximately 10.13% of the common shares in circulation on June 6, 2022. The 700,000 shares distributed The shares represent approximately 1.67% of the ordinary shares in circulation.
Immediately following the disposition of the Distributed Shares, the Versant Funds beneficially own and control or direct 3,544,862 Common Shares, representing approximately 8.46% of the Common Shares outstanding. Thus, effective June 6, 2022, the Versant Funds ceased to be reporting insiders of the Company within the meaning of NI 55-104 – Insider reporting requirements and exemptions.
The Versant Funds reserve the right, depending on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional Common Shares or other securities of the Company, to dispose of any or all of the common stock Shares or other securities of the Company which it may hold from time to time, in each case in connection with open market or private transactions, sales in block or otherwise or in connection with ordinary exchange transactions effected through one or more brokers, either individually or using pricing or other instructions (including through customary Rule 10b5-1 programs ), and review or reconsider their position, change their purpose, take other action, or formulate and implement plans or proposals regarding any of the foregoing.
The Versant Funds intend to review their investment in the Company from time to time based on a variety of factors, including the Company’s business, financial condition, results of operations and prospects, general economic and industry conditions. , the securities markets in general and those of the Company’s shares in particular, as well as other developments.
An alert statement will be filed by the Versant Funds in accordance with applicable securities laws and will be available on SEDAR under the Company’s profile at www.sedar.com or can be obtained directly from Versant Funds upon request at the telephone number below. The head office of the Company is located at 7210 Frederick-Banting, Suite 100, Montreal, Quebec H4S 2A1. The address of each of the Versant Funds is One Sansome Street, Suite 3630, San Francisco, CA 94104. Each of the Versant Funds is organized under the laws of Delaware. with the exception of Versant Venture Capital V (Canada) LP which is incorporated under the laws of Ontario, Canada. The primary business of the Versant Funds is to invest in biotechnology companies.
Steve Edelson, Vice President, Investor Relations and Communications